AI Is Making Body Scans Cheaper. Medicine Still Has to Decide What They’re For.

A $4,499 body scan is not just a price tag. It is a signal.

Presented By Our Partners

It says that a certain kind of medicine is moving out of the hospital referral pathway and into the consumer marketplace. Full-body MRI, subscription bloodwork, body-composition analysis, “executive” screening bundles and AI-assisted imaging are being packaged less like traditional diagnostics and more like a premium operating system for the self.

The appeal is obvious. If modern medicine can see disease earlier, why wait for symptoms? If AI can make MRI faster and cheaper, why reserve advanced imaging for people who are already sick? If bloodwork can be tracked longitudinally, why settle for a once-a-year snapshot? If a hidden tumor, aneurysm or metabolic problem can be found before it becomes catastrophic, who would not want to know?

That is the emotional power behind the new full-body scan economy.

But healthcare has a way of punishing simple stories. Cheaper discovery is not automatically better medicine. A scan can find disease. It can also find uncertainty. It can create a patient where, five minutes earlier, there was only a person. It can produce reassurance, anxiety, lifesaving detection, unnecessary follow-up, or all of those at once.

That is why the more important question is not whether AI can make body scans cheaper.

It probably can.

The harder question is what medicine should do once those scans become cheap enough for millions of people to consider.

From luxury scan to consumer product

Concierge medicine, full-body MRIs and subscription bloodwork are increasingly being sold as personalized healthcare at a fraction of what high-end medicine once cost.

That phrase — “at a fraction of the price” — is doing a lot of work.

For years, elective full-body MRI lived in the same psychological category as private longevity clinics, executive physicals and celebrity wellness. Prenuvo helped popularize that version of the market, offering whole-body MRI scans that commonly cost thousands of dollars out of pocket. Recent pricing guides and consumer coverage have described packages ranging from about $999 for limited scans to roughly $2,499 for a comprehensive whole-body scan, with higher-end bundles reaching around $3,999 to $4,499 in some markets.

Then the price began to move.

Function Health acquired Ezra in 2025 and announced a $499 full-body MRI offering built around Ezra’s FDA-cleared AI image-enhancement technology. Ezra had previously charged much more for elective full-body MRI. The new pitch was simple: AI could reduce scan time from about an hour to 22 minutes and cut the price dramatically. Function already sold broad lab testing to members; imaging would complete the picture.

The three names matter because they represent different versions of the same shift. Prenuvo is the premium, dedicated whole-body MRI brand. Ezra built around AI-assisted full-body MRI and partnerships with imaging centers. Function Health began as a broad lab-testing and health-tracking platform, then moved into imaging by acquiring Ezra. Together, they show how preventive diagnostics are being bundled into consumer-facing health platforms.

This is the real shift. The market is not only selling scans. It is selling a new model of preventive self-surveillance: labs plus imaging plus longitudinal tracking plus algorithms plus a dashboard.

The companies call it democratization. Critics call it overtesting. Both descriptions can contain some truth.

A $4,499 scan is a luxury good. A $499 scan starts to look like a mass-market product. That price compression changes the debate.

When only a small number of wealthy consumers buy elective scans, the question is mostly whether those consumers are wasting money. When AI lowers the cost enough for far more people to participate, the question becomes whether the healthcare system has any coherent plan for what happens next.

AI can lower the friction

AI has a plausible role in making MRI faster and cheaper.

MRI is powerful but expensive. Scanner time is scarce. Radiologist time is scarce. Long protocols, specialized sequences and careful reads all add cost. If AI can help acquire usable images faster, reduce noise, support reconstruction, assist segmentation or streamline reporting, the economics can change.

That is what companies such as Ezra and Function are betting on. Ezra’s Flash AI has received FDA 510(k) clearance for enhancing MRI image quality, and the company has described the technology as a path toward shorter, lower-cost scans. Prenuvo has also emphasized proprietary MRI protocols, radiologist expertise, AI-enabled analysis and a growing body of internal or presented evidence around its screening program.

There is nothing unserious about the technical direction. Faster acquisition and better image processing are real advances. Radiology has always been shaped by improvements in hardware, protocols, reconstruction and interpretation. AI belongs in that lineage.

But a cheaper MRI is not the same thing as a useful screening program.

That distinction matters because the consumer story and the medical story are not identical. The consumer story says: more information, earlier, for less money. The medical story asks: for whom, for what condition, at what risk level, with what downstream pathway, at what cost, and with what evidence of improved outcomes?

Those are less glamorous questions. They are also the ones that decide whether a technology becomes medicine.

Screening is not the same as seeing

The appeal of full-body MRI rests on a basic intuition: seeing more of the body should help catch more disease.

Sometimes that is true. In high-risk patients, people with known cancer predisposition syndromes, certain staging or surveillance contexts, or specific clinical indications, whole-body MRI can be useful. Medicine already uses advanced imaging when the risk profile and clinical question justify it.

The controversy is average-risk screening: scanning people without symptoms, without a specific medical concern, and without a risk profile that clearly changes the odds.

That is where medical societies have been cautious. The American College of Radiology stated in 2023 that there is not enough evidence to recommend total-body MRI screening for people without symptoms, risk factors or a family history suggesting serious disease or injury. Preventive-medicine voices have raised similar concerns: when disease is uncommon in a screened population, even a sophisticated test can generate many findings that do not become clinically meaningful.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

That is the paradox of screening healthy people. The healthier the population, the harder it becomes to know whether the abnormality you found is a rescue or a trap.

A small kidney mass may matter. A liver lesion may be benign. A thyroid nodule may never cause harm. A tiny possible aneurysm may trigger months of worry and repeat imaging. A spinal abnormality may explain nothing. A “negative” scan may reassure someone who still needs colonoscopy, mammography, skin checks, blood pressure control, lipid management or ordinary primary care.

The scan sees anatomy. Medicine has to decide significance.

The incidentaloma economy

Every broad screening technology creates its own shadow economy.

A full-body MRI does not end when the report is delivered. It may begin there.

Unexpected findings can lead to follow-up imaging, specialist consultations, biopsies, lab tests, repeat scans, surveillance plans and insurance arguments. Some of that follow-up is appropriate. Some is not. The problem is that it is difficult to know which is which at the moment the abnormality appears on the report.

Radiologists call these unexpected findings incidental findings. Patients often experience them differently: as a threat, a mystery, a ticking clock or a new identity.

This is the part of the body-scan market that deserves more attention. The companies sell detection. The healthcare system absorbs consequence.

If an elective scan finds a suspicious lesion, the patient may bring it to a primary-care doctor who did not order the scan, may not agree with the premise of the scan, and now has to help manage the uncertainty. A specialist may be asked to evaluate a finding discovered outside a conventional clinical pathway. An insurer may decline to cover follow-up. A patient may pay cash for the scan but expect insurance to cover the cascade.

That cascade is not always bad. Sometimes it finds a cancer early. Sometimes it catches an aneurysm. Sometimes it gives a patient a baseline that becomes useful later.

But sometimes it turns ordinary variation into medical work.

That is the delivery problem hiding inside the discovery promise.

The affordability question cuts both ways

At first glance, lower scan prices look like an affordability win. A $499 scan is meaningfully different from a $4,499 bundle. If AI can lower the cost of advanced imaging, that is worth paying attention to.

Healthcare is full of diagnostic bottlenecks. People delay care because they cannot afford imaging. Prior authorization slows diagnosis. Rural areas lack specialty access. Patients with unclear symptoms sometimes spend months moving through fragmented referrals before someone gets the right image.

In that world, cheaper, faster imaging could be genuinely valuable.

But affordability in healthcare is not just the price of the first test. It is the price of the entire pathway.

A low-cost scan that triggers a high-cost cascade may not be affordable. A cheap screening test that leads to unnecessary biopsies, repeat imaging or specialist visits may shift costs rather than reduce them. A scan paid out of pocket by a wealthy consumer may create downstream claims in the insured system. A negative scan that replaces proven screening may become expensive in a different way.

The affordability question is therefore not: how cheap can the scan get?

It is: can the scan be used in a way that improves outcomes without creating avoidable cost, anxiety and waste?

That is a much harder standard.

Baselines are the strongest argument

The strongest argument for consumer imaging may not be one-time cancer detection. It may be longitudinal comparison.

A single scan can create uncertainty. A baseline can create context.

If a person has a known benign lesion, a stable vascular finding, a pattern of body composition, fatty liver changes, spinal degeneration or other measurable features, future scans may be easier to interpret. Change over time can be more meaningful than a single abnormality. That is one reason companies emphasize tracking: the body becomes a time series.

This argument deserves to be taken seriously. Medicine already uses longitudinal data constantly. A rising PSA, changing mole, growing nodule, worsening ejection fraction or shifting lab trend can matter more than one isolated result.

But baselines also require discipline.

Who decides the interval? What findings merit surveillance? What protocol is used each time? Are scans comparable across machines and vendors? Who stores the images? Who explains the uncertainty? Who pays for repeat imaging? What happens if a consumer switches platforms? How are benign findings prevented from becoming permanent anxiety generators?

A baseline is not just data. It is a commitment to interpretation.

The evidence gap is not anti-innovation

Skepticism about full-body MRI is sometimes framed as institutional medicine resisting prevention. That is too easy.

The better critique is that prevention is not proven by intention. It is proven by outcomes.

A screening program has to show that it finds meaningful disease early enough to change what happens, in a population where the benefits outweigh the harms. It has to account for false positives, false negatives, overdiagnosis, downstream procedures, cost-effectiveness and patient experience. It has to define who should be screened and who should not.

That is why colonoscopy, mammography, cervical cancer screening and lung cancer screening are governed by age, risk and evidence-based intervals. They are imperfect, debated and updated over time, but they are not simply “more testing is better.”

Full-body MRI has not yet earned that kind of role for average-risk adults.

That does not mean it never will. The market is moving quickly. Imaging protocols are improving. AI may reduce cost and scan time. Companies may produce better outcome studies. Specific populations may emerge where the benefit is clearer. Hybrid models that combine risk stratification, labs, genomics, family history and targeted imaging may prove more rational than scanning everyone the same way.

But until that evidence matures, the responsible position is neither blanket rejection nor breathless adoption.

It is conditional curiosity.

What a useful system would look like

If AI-assisted body scans are going to become part of serious healthcare, they need more than marketing.

They need clear indications. Average-risk people, high-risk people, symptomatic people and patients with known predispositions should not be treated as one market segment.

They need transparent reporting. Patients should understand what the scan includes, what it excludes, what it is good at, what it is poor at, and what kinds of findings are common.

They need follow-up pathways. A scan provider should not simply hand off uncertainty to an overburdened primary-care system without a plan.

They need evidence registries. If companies scan hundreds of thousands of people, they should be able to show what was found, what was confirmed, what was false positive, what care was triggered, what outcomes changed and what costs followed.

They need integration with proven screening. A full-body MRI should not become a consumer substitute for colonoscopy, mammography, cervical screening, lipid management, blood pressure control or ordinary medical care.

They need affordability measured across the whole cascade, not just the headline price.

Most of all, they need humility. The body is not a dashboard. Medicine is not a treasure hunt. More information helps only when someone knows what to do with it.

Discovery still has to become delivery

The full-body scan market is easy to mock because its marketing can feel like medicine for the worried wealthy. But dismissing it entirely would miss the more important signal.

A real shift is underway. Diagnostics are becoming more consumer-facing. AI is lowering technical barriers. Labs, imaging and longitudinal tracking are being bundled into subscription products. Patients are becoming buyers of discovery before they become patients in the traditional sense.

That shift will not disappear.

The task now is to make it medically coherent.

If AI makes advanced imaging cheaper, healthcare cannot simply pretend the old referral gates will hold forever. But it also cannot let a consumer marketplace define prevention by whatever can be sold at scale.

The future worth building is not one where every healthy person buys a body scan every year because the price dropped. It is one where better risk models, better imaging, better evidence and better follow-up pathways help the right people get the right test at the right time — and then actually receive the right care.

That is the line between medical discovery and medical noise.

AI can make the scan cheaper. Medicine still has to decide what it is for.

Source notes

• Function Health / Ezra acquisition coverage via PR Newswire, CNBC, Fierce Healthcare and Radiology Business.
• American College of Radiology, 2023 statement on screening total-body MRI.
• Radiology Today, “Looking for Trouble,” on whole-body MRI screening, false positives and medical-society concerns.
• Fred Hutch / UW Medicine radiology commentary on whole-body MRI screening and incidental findings.
• Prenuvo public materials and pricing/FAQ pages.
• Consumer and healthcare-industry reporting on Prenuvo, Ezra, Function Health and full-body MRI screening.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.